 | |
- close
- close
|
Suggest other news sources for this topic
WIKI ANALYSIS
 |
This article describes a concept which could impact a variety of companies, countries or industries. To see what companies and articles reference this concept page, click here. |
Influenza, or the flu, is a common infectious disease, which can be deadly to individuals with compromised immune systems (the very young, the very old, and those with conditions such as AIDS or Cancer). However, occasionally particularly virulent strains of influenza break out that can be threatening on a much larger scale -- such as the flu epidemic of 1918 and, more recently, concerns that H5N1 "Bird Flu" or H1N1 "Swine Flu" could mutate into a highly-infectious and deadly virus. A number of pharmaceutical companies make treatments for the flu and benefit from the fear of a flu outbreak.
- Roche Pharmaceuticals makes Tamiflu, an antiviral pill to treat the flu. In 2005, amid concerns that bird flu might pose a large threat during the winter flu season, many national governments began stocking up on Tamiflu. Chugai pharmaceuticals sells Tamiflu in Japan.
- GlaxoSmithKline (GSK) makes a flu drug called Relenza. Biota Holdings (BTA-AU) licensed Relenza to Glaxo.
- Novartis AG (NVS), through its acquisition of Chiron in 2006, supplies much of the traditional flu vaccine supply to the United States.
- AstraZeneca (AZN), through recently acquired MedImmune, manufactures 'FluMist', a novel flu vaccine that is delivered via an intranasal spray rather than via an injection.
Companies with treatments for H1N1, or "Swine Flu"
In April 2009, a novel flu virus, known as "Swine Flu" because it was believed to have originated in pigs, started infecting humans. By April 28th, there were 1,300 confirmed cases of the flu, known by its scientific designation H1N1, in Mexico, and a handful in the U.S. and other parts of the world.
According to preliminary test done by the US Center for Disease Control, Roche Pharmaceuticals (RHHBY)'s Tamiflu and GlaxoSmithKline (GSK)'s Relenza are active against H1N1, although many older drugs are not. [1]
References
| ||||||
|
|
